The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.
September 23rd 2024
The WHO updated its cervical cancer prevention guidelines to include CINtec PLUS Cytology, a dual-stain cytology test.
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
2023 ASCO Direct™ Highlights: Practice-Changing Data From the Leading Oncology Conference
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
PER LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable ...
November 16, 2024
Register Now!
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition
December 6, 2024
Register Now!
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Atezolizumab Plus Bevacizumab/Chemo Fails to Significantly Improve PFS in Ovarian Cancer
The addition of atezolizumab to a backbone comprised of bevacizumab and chemotherapy failed to significantly improve progression-free survival in patients with newly diagnosed stage III/IV ovarian cancer.
Dr. Coleman on the Clinical Implications of the innovaTV 204 Trial in Cervical Cancer
September 21st 2020Robert L. Coleman, MD, FACOG, FACS, discusses the clinical implications of the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 trial in women with previously treated recurrent or metastatic cervical cancer.
Tisotumab Vedotin Elicits Encouraging Responses in Recurrent/Metastatic Cervical Cancer
Tisotumab vedotin demonstrated an objective response rate of 24% in patients with recurrent and/or metastatic cervical cancer who were previously treated with doublet chemotherapy and bevacizumab, if eligible.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for olaparib as maintenance treatment in adult patients with advanced, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response after first-line platinum-based chemotherapy plus bevacizumab and whose disease has homologous recombination deficiency positivity defined by either a BRCA1/2 mutation and/or genomic instability.
QoL Maintained in Patients With Gynecologic Malignancies Treated on PRIMA Trial
September 20th 2020Quality of life according to patient-reported outcomes was not reduced despite treatment toxicities in those with ovarian, primary peritoneal, or fallopian tube cancer treated with niraparib versus placebo in the PRIMA/ENGOT-OV26/GOG-3012 trial.
Balstilimab Monotherapy or Plus Zalifrelimab Active in Recurrent/Metastatic Cervical Cancer
The investigative PD-1 inhibitor balstilimab as a single agent and combined with the CTLA-4 inhibitor zalifrelimab showed promising objective response rates, regardless of PD-L1 expression, and a tolerable safety profile in patients with recurrent/metastatic cervical cancer.
Niraparib Granted Positive EU Opinion for Frontline Maintenance in Advanced Ovarian Cancer
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for niraparib for frontline maintenance treatment in patients with advanced ovarian cancer who are responsive to platinum-based chemotherapy.
FDA Approves Expanded Use of CINtec PLUS Cytology Test to Prevent Cervical Cancer in HPV+ Women
The FDA has approved the expanded use of the CINtec PLUS Cytology assay for women who undergo cervical cancer screening and test positive for high-risk types of human papillomavirus.
STRO-002 Shows Early Efficacy, Safety in Heavily Pretreated Epithelial Ovarian Cancer
The novel anti-folate receptor alpha antibody-drug conjugate STRO-002 demonstrated encouraging efficacy with a tolerable safety profile in patients with advanced platinum-resistant or refractory epithelial ovarian cancer.
Niraparib Approved in China for Frontline Maintenance in Ovarian Cancer
The China National Medical Products Administration has approved niraparib for use as a first-line maintenance treatment in adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who achieve a complete or partial response to first-line platinum-based chemotherapy.
Herzog and Moore Mull Over the Role of Maintenance PARP Inhibition in Ovarian Cancer
September 7th 2020In our exclusive interview, Thomas Herzog, MD, and Kathleen Moore, MD, reviewed the topline results of the 4 positive PARP inhibitor trials in the frontline maintenance setting and provided perspective on the potential applications of these data to clinical practice.
Avelumab Demonstrates Favorable Activity in Gestational Trophoblastic Tumors
September 3rd 2020Benoit You, MD, PhD, discusses the need for novel and well-tolerated agents in chemotherapy-resistant gestational trophoblastic tumors and ongoing research efforts designed to bring avelumab to the forefront of the treatment paradigm.
Coleman and Slomovitz Continue the Discussion on Maintenance PARP Inhibition in Ovarian Cancer
September 3rd 2020In our exclusive interview, Robert L. Coleman, MD, FACOG, FACS and Brian M. Slomovitz, MD, discussed the benefits and limitations of PARP inhibition in all-comers with newly diagnosed advanced ovarian cancer and pivotal PARP inhibitor trials in the frontline setting.
Surgery-Free Alternative Is Favorably Accepted Among Women at Risk of Ovarian Cancer
August 26th 2020The majority of women at a high risk of developing ovarian cancer reported having a favorable attitude toward adopting a two-step risk-reducing early salpingectomy and delayed oophorectomy instead of a risk-reducing salpingo-oophorectomy.
Trastuzumab Duocarmazine Under Exploration in HER2+ Endometrial Cancer
August 25th 2020Investigators are evaluating the safety and efficacy of the investigational antibody-drug conjugate vic-trastuzumab duocarmazine in patients with HER2-expressing recurrent, advanced, or metastatic endometrial cancer in the phase 2 SYD985.003 trial.
Moore Highlights Hope for Mirvetuximab Soravtansine in FRα-High Ovarian Cancer
August 25th 2020In an interview with OncLive, Kathleen Moore, MD, discusses the MIRASOL trial and the hope for mirvetuximab soravtansine in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high FRα expression.
Phase 3 OVAL Trial With VB-111 in Platinum-Resistant Ovarian Cancer to Continue
The independent data safety monitoring committee has unanimously recommended that the phase 3 OVAL trial examining VB-111 in patients with platinum-resistant ovarian cancer continue as planned.
Dizon Discusses Elements of Sexual Health in Gynecologic Cancer
August 6th 2020In our exclusive interview, Don S. Dizon, MD, FACP, FASCO, discusses the primary physical and residual psychological effects of gynecologic cancers on women’s sexual health, the challenges of broaching these topics in the clinic, and the role oncologists play in helping patients manage these difficulties.